Head-to-head evidence
Daprodustat vs SSS17
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline
Daprodustat · Jesduvroq
Marketed by GlaxoSmithKline
NCT02876835 · Phase 3 · completed
This was a large randomized Phase 3 trial comparing oral daprodustat with darbepoetin alfa in 3,872 non-dialysis chronic kidney disease patients with anemia, conducted open-label — neither participants nor investigators were blinded to assignment. Although the active-comparator design was otherwise robust, the two pre-specified non-inferiority primary endpoints were both achieved: time to MACE (HR 1.03; 95% CI 0.89–1.19, within the 1.25 margin) and change in hemoglobin over weeks 28–52 (LS mean difference 0.08 g/dL; 95% CI 0.03–0.13, within the -0.75 g/dL margin). Because the trial was not blinded, this is solid but not top-tier evidence; secondary superiority analyses of cardiovascular outcomes were not statistically significant.
SSS17
Developed by Shenyang Sunshine Pharmaceutical
NCT07014631 · Phase 2 · completed
The study randomized 86 participants to SSS17 or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in hemoglobin, a laboratory surrogate measure, and the comparison has not been reported, so no conclusion can yet be drawn about whether the endpoint was met.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Daprodustat's landscape · SSS17's landscape